US OptionsDetailed Quotes

GMAB250516P15000

Watchlist

0.10
0.000.00%

15min DelayTrading Apr 14 11:18 ET

0.00High0.00Low

Genmab Stock Discussion

Teddy123

May 2 12:49

Genmab to Submit Supplemental Biologics License Application (sBLA) to U.S. Food and Drug Administration for Epcoritamab Plus Rituximab and Lenalidomide (R²) in Patients with Relapsed/Refractory Folli

$Genmab (GMAB.US)$
Genmab's New Lymphoma Treatment Achieves Breakthrough Results in Phase 3 Trial, FDA Filing Imminent

$Genmab to Submit Supplemental Biologics License Application (sBLA) to U.S. Food and Drug Administration for Epcoritamab Plus Rituximab and Lenalidomide (R²) in Patients with Relapsed/Refractory Folli$

Teddy123

Apr 1 05:27

TIVDAK® (tisotumab vedotin) Approved by European Commission for Previously Treated Recurrent or Metastatic Cervical Cancer

$Genmab (GMAB.US)$
Breakthrough: New EU-Approved Cancer Drug Cuts Death Risk by 30% - First of its Kind for Cervical Cancer

Teddy123

Mar 31 23:43

TIVDAK® (tisotumab vedotin) Approved by European Commission for Previously Treated Recurrent or Metastatic Cervical Cancer

$Genmab (GMAB.US)$
Breakthrough: New EU-Approved Cancer Drug Cuts Death Risk by 30% - First of its Kind for Cervical Cancer

Teddy123

Mar 18 09:26

Investigational Rinatabart Sesutecan (Rina-S®) Continues to Show Encouraging Antitumor Activity in Patients with Advanced Ovarian Cancer

$Genmab (GMAB.US)$
Breakthrough: New Ovarian Cancer Drug Achieves Remarkable 55% Response Rate in Clinical Trial

Teddy123

Mar 10 22:24

Genmab Announces Johnson & Johnson Decision Regarding HexaBody®-CD38

$Genmab (GMAB.US)$
Genmab Announces Johnson & Johnson Decision Regarding HexaBody®-CD38

Barish

Feb 27 00:04

$Genmab (GMAB.US)$ can it touch 24? or it will drop more? since opens low today🙄

Teddy123

Feb 20 21:15

EPKINLY® (epcoritamab) Approved by Japan Ministry of Health, Labour and Welfare for Additional Indication as a Treatment for Relapsed or Refractory Follicular Lymphoma

$Genmab (GMAB.US)$
Breakthrough Lymphoma Drug EPKINLY Scores Dual Approval in Japan: 95% Patient Response

$EPKINLY® (epcoritamab) Approved by Japan Ministry of Health, Labour and Welfare for Additional Indication as a Treatment for Relapsed or Refractory Follicular Lymphoma$

Stock_Drift

Sep 15, 2024 22:58

$Genmab (GMAB.US)$

亿顺利发春2888

Jul 12, 2024 21:38

$Genmab (GMAB.US)$ growth up positive trend

亿顺利发春2888

Jul 11, 2024 21:53

$Genmab (GMAB.US)$ positive growth $26, growth upwards trend

No comment yet